Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains
- 23 February 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (4) , 959-963
- https://doi.org/10.1016/j.bmcl.2003.12.008
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- AmprenavirDrugs, 2000
- Amprenavir: A new human immunodeficiency virus type 1 protease inhibitorClinical Therapeutics, 2000
- Resistance to Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitorsAntimicrobial Agents and Chemotherapy, 1995